Sharemaestro Newsreel

Nephros Schedules Second Quarter 2026 Financial Results Conference Call

Nephros, Inc. announced it will file its second quarter financial results on Thursday, August 06, 2026, after market close and will host a conference call on the same day at 4:30 pm ET. The company is a leading water technology provider, offering filtration solutions …

Envista Holdings (NYSE: NVST) doubles Q2 2026 profit on higher sales and cash flow

Envista Holdings (NYSE: NVST) reported a strong Q2 2026, doubling its net profit to $53.7 million compared to the previous year, driven by a 7.1% increase in sales to $730.5 million. The company's gross margin improved to 55.7% and operating margin to 11.0%, boosted …

Envista Q2 2026 Earnings: Margin Expansion Supports Higher Guidance

Envista Holdings (NYSE: NVST) reported strong Q2 2026 earnings with revenue up 7.1% to $730.5 million and diluted EPS more than doubling. The company saw significant margin expansion across both GAAP and adjusted bases, driven by operational execution and a tariff refund, leading to …

Solventum May Separate Software Used by More Than 75% of U.S. Hospitals

Solventum (NYSE: SOLV) announced its intent to separate its Health Information Systems (HIS) business, generating $1.4 billion in annual sales and serving over 75% of U.S. hospitals. This move is part of a three-phase transformation strategy aimed at optimizing its portfolio and maximizing shareholder …

California State Teachers Retirement System Raises Holdings in Repligen Corporation $RGEN

The California State Teachers Retirement System increased its stake in Repligen Corporation (NASDAQ:RGEN) by 22.1% in the first quarter, now holding 61,860 shares valued at $7.3 million. Repligen exceeded analyst expectations with quarterly revenue of $204.13 million and earnings of $0.54 per share, and …

Royal Gold Repays $200M Debt and Buys Back 147,205 Shares

Royal Gold, Inc. (NASDAQ: RGLD) announced strong financial results for the second quarter ended June 30, 2026, including a record operating cash flow of $335.2 million. The company repaid $200 million on its revolving credit facility, repurchased 147,205 shares for $30 million, and increased …

Nyxoah Q2 2026 Earnings Call Transcript

Nyxoah reported strong Q2 2026 results with worldwide revenue growing 21% sequentially to €7.7 million, driven by accelerated U.S. commercialization where active accounts doubled and prior authorizations increased by 77%. The company strengthened its balance sheet with $110 million in financing and maintained its …

Nyxoah Reports Second Quarter and First Half 2026 Financial and Operating Results

Nyxoah announced its Q2 and H1 2026 financial and operating results, showing significant growth with U.S. net revenue increasing by 22% sequentially and global net revenue by 21%. The company secured $110 million in financing and reported strong commercial indicators for its Genio system, …

Why Pulse Biosciences (PLSE) Is Up 6.4% After NANOPULSE-AF Trial Hits Enrollment Midpoint And What It Means

Pulse Biosciences (PLSE) saw its stock rise 6.4% after its NANOPULSE-AF pivotal study for atrial fibrillation reached its enrollment midpoint, demonstrating rapid recruitment and clinician enthusiasm for its nPulse System. This milestone provides clearer insight into future pivotal data, which could impact reimbursement and …

KORU Medical Systems Announces Second Quarter 2026 Results and Updates Full Year 2026 Guidance

KORU Medical Systems reported strong second-quarter 2026 financial results, with net revenues growing 18% to $12.0 million and net income improving 222% to $0.25 million. The company updated its full-year 2026 guidance, projecting revenues between $47.5 - $48.5 million and positive adjusted EBITDA. Key …

Staar Surgical (STAA) Upgraded to Strong Buy: What Does It Mean for the Stock?

Staar Surgical (STAA) has been upgraded to a Zacks Rank #1 (Strong Buy), indicating an upward trend in its earnings estimates. This upgrade suggests positivity about its earnings outlook, which could lead to increased buying pressure and a rise in its stock price. The …

LeMaitre Vascular Down Over 22%, On Track for Largest Percent Decrease Since October 2008 -- Data Talk

LeMaitre Vascular Inc. (LMAT) experienced a significant drop of over 22%, trading at $82.06, which would mark its lowest close since January 2026. This decline puts the company on track for its largest percentage decrease since October 2008. The stock is down 30.1% from …

Becton Dickinson earnings on deck as growth questions linger

Becton Dickinson (BD) is set to report its fiscal fourth-quarter earnings, with investors focused on the company's transformation into a pure-play medtech business. Analysts are looking for signs of sustainable mid-single-digit growth and improved operating leverage following the spin-off of its Biosciences and Diagnostic …

Stevanato Group S.p.A. Stock 12‑Month Price Target Raised to $25.1, Implies 28% Upside

Stevanato Group S.p.A.'s average stock price target has been raised from $24.95 to $25.1 by 10 analysts, suggesting a potential 28% upside from the August 4th closing price. The consensus rating among 12 covering analysts remains a "Buy," with 10 Buys and 2 Holds. …

Biolife Solutions stock hits 52-week high at 33.18 USD

BioLife Solutions Inc. (NASDAQ:BLFS) stock recently hit a 52-week high of $33.18, reflecting a 56.33% increase over the past year and a current market capitalization of $1.61 billion. Despite strong revenue growth and analyst predictions of profitability, InvestingPro analysis suggests the stock may be …

Solventum under pressure to prove growth in earnings report By Investing.com

Solventum Corp. is under pressure to demonstrate organic growth in its upcoming second-quarter earnings report. Investors are keenly watching for sustained growth momentum across its segments, improved profitability, and how the company is managing pricing pressures, especially after outperforming expectations in its first quarter.

Solventum (NYSE:SOLV) Posts Better-Than-Expected Sales In Q2 CY2026

Solventum (NYSE:SOLV) reported better-than-expected Q2 CY2026 results, with sales up 2.2% year-on-year to $2.21 billion, beating analyst estimates. Its non-GAAP profit of $2.55 per share also significantly surpassed consensus estimates, leading management to raise its full-year Adjusted EPS guidance. Despite short-term revenue growth and …

Envista’s (NYSE:NVST) Q2 CY2026 Sales Beat Estimates

Envista Holdings (NYSE: NVST) reported strong Q2 CY2026 results, surpassing revenue and adjusted EPS expectations. The dental products company achieved 7.1% year-on-year sales growth and a non-GAAP profit significantly above analyst estimates, leading management to raise its full-year Adjusted EPS guidance. Despite a tepid …

LeMaitre Vascular (NASDAQ:LMAT) Price Target Cut to $94.00 by Analysts at Wells Fargo & Company

Wells Fargo & Company analysts have cut their price target for LeMaitre Vascular (NASDAQ:LMAT) to $94.00 from $104.00, maintaining an "equal weight" rating. This adjustment follows the company's recent earnings report where Q2 EPS of $0.74 missed the consensus estimate of $0.81, and revenue …

The Cooper Companies (COO) Upgraded to Buy: Here's What You Should Know

The Cooper Companies (COO) has been upgraded to a Zacks Rank #2 (Buy), reflecting an upward trend in its earnings estimates. This upgrade is significant because a company's changing earnings picture is a strong indicator of future stock price movement. The company's earnings estimates …

Stevanato Group Details Mid-2026 Performance and Risk Landscape in Unaudited Interim Report

Stevanato Group has filed an unaudited interim report for Q2 2026, outlining its financial performance and discussing key operational risks such as supply chain issues, geopolitical tensions, and post-pandemic demand normalization. The report emphasizes the importance of quality, innovation, and brand reputation for competitiveness. …

Sanara MedTech (SMTI) Expected to Post Earnings on Wednesday

Earnings call transcript: Azenta tops Q3 2026 estimates, shares edge higher

Two Merit Medical fireside chats will stream live Aug. 11-12

Merit Medical Systems, Inc. (NASDAQ: MMSI) announced its participation in two investor conferences in August 2026. Management will host a fireside chat at the Canaccord Genuity 46th Annual Growth Conference on August 11 and at the Bank of America SMID Cap Conference on August …

STAAR Surgical appoints Warren Foust as permanent CEO

STAAR Surgical has appointed Warren Foust as its permanent CEO, following a period of leadership uncertainty after the collapse of Alcon's $1.6 billion takeover bid. Foust, who previously served as interim co-CEO and president, will continue as president, while Deborah Andrews resumes her role …

Azenta Q3 2026 EPS Tops Expectations, Revenue Up 12%

Azenta, Inc. reported strong Q3 2026 results, with Non-GAAP Diluted EPS of $0.16, significantly exceeding Wall Street's estimate of $0.12. The company's revenue rose 12.0% year-over-year to $161.2M, primarily driven by impressive organic growth of 9.0% and strong performance in its Sample Management Solutions …

Cooper Companies Inc (COO) Earnings Forecast: Future EPS & Revenue Growth Estimates

This article provides an earnings forecast for Cooper Companies Inc (COO), highlighting its current earnings forecast score of 7.58 and ranking within the Healthcare Equipment & Supplies industry. It details analyst ratings, target prices, and expected revenue and EPS for upcoming periods, indicating a …

Trading Systems Reacting to (SOLV) Volatility

The article discusses the volatility of Solventum Corporation (NASDAQ: SOLV) and presents AI-generated trading strategies. It highlights strong near and mid-term sentiment, potential for upside, and provides specific entry, target, and stop-loss levels for position, momentum breakout, and risk hedging strategies. The analysis includes …

LeMaitre Vascular, Inc. (NASDAQ:LMAT) Announces $0.25 Quarterly Dividend

LeMaitre Vascular, Inc. (NASDAQ:LMAT) declared a quarterly dividend of $0.25 per share, payable on September 3rd to shareholders of record on August 20th. This announcement comes despite the company missing analyst expectations for both Q2 revenue and EPS, and subsequently lowering its full-year 2026 …

Curious about ResMed (RMD) Q4 Performance? Explore Wall Street Estimates for Key Metrics

Wall Street analysts project that ResMed (RMD) will report Q4 earnings of $2.90 per share, an increase of 13.7% year-over-year, with revenues expected to reach $1.46 billion, up 8.4%. The consensus EPS estimate has seen a slight downward revision of 0.1% over the last …

President of Aptar Closures Of AptarGroup Sold 37% Of Their Shares

Hedi Tlili, the President of Aptar Closures at AptarGroup, recently sold shares worth US$1.2 million, reducing his holding by 37%. While this is the largest insider sale within the last year for AptarGroup, it doesn't necessarily indicate a negative outlook on the company, as …

Henry Schein, Inc. (HSIC) Hits Fresh High: Is There Still Room to Run?

Henry Schein, Inc. (HSIC) recently hit a new 52-week high of $92.18, with shares up 2.6% over the past month and 17.9% year-to-date. The company has consistently beaten earnings estimates, reporting strong EPS and revenue growth. With a Zacks Rank of #2 (Buy) and …

STAAR Surgical (STAA) to Post Earnings on Wednesday

AtriCure (ATRC) insider plans NASDAQ sale of 3,564 awarded shares

AtriCure, Inc. insider Karen Prange has filed a notice of intent to sell 3,564 shares of common stock on NASDAQ, which were awarded on May 26, 2023. This Form 144 filing indicates that the shares are held through Fidelity Brokerage Services LLC. Over the …

335,493 Shares in Stevanato Group S.p.A. $STVN Purchased by Confluence Investment Management LLC

Confluence Investment Management LLC has purchased a new stake of 335,493 shares in Stevanato Group S.p.A., valued at approximately $6.06 million, representing 0.11% of the company. Other institutional investors like Conestoga Capital Advisors, Van Berkom & Associates, Jennison Associates, and Roubaix Capital also increased …

Have Kestra Medical Technologies Insiders Been Selling Stock?

Kestra Medical Technologies founder Brian Webster recently sold shares worth approximately US$692k, accounting for 7.1% of his holding. While this was the largest insider sale in the past year, the selling price was below the current market price, which can be seen as a …